Applied Genetic Technologies Corporation (AGTC) Income Statement Analysis

See more : Affimed N.V. (0HL9.L) Income Statement Analysis – Financial Results

Complete financial analysis of Applied Genetic Technologies Corporation (AGTC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Applied Genetic Technologies Corporation, a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Scatec ASA (0R3I.L) Income Statement Analysis – Financial Results
Switching Technologies Gunther Limited (SWITCHTE.BO) Income Statement Analysis – Financial Results
Towngas Smart Energy Company Limited (TGASF) Income Statement Analysis – Financial Results
Monalisa Co., Ltd (012690.KS) Income Statement Analysis – Financial Results
Affluent Partners Holdings Limited (MNNGF) Income Statement Analysis – Financial Results

Applied Genetic Technologies Corporation (AGTC)

Industry: Biotechnology

Sector: Healthcare

Website: https://agtc.com

About Applied Genetic Technologies Corporation

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.

Metric	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	325.00K	500.00K	2.45M	41.69M	24.19M	39.47M	47.36M	2.35M	1.13M	942.00K	1.08M
Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	325.00K	500.00K	2.45M	41.69M	24.19M	39.47M	47.36M	2.35M	1.13M	942.00K	1.08M
Gross Profit Ratio	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Research & Development	49.52M	44.40M	35.78M	33.18M	32.18M	26.22M	38.86M	16.53M	8.50M	3.13M	2.35M
General & Administrative	16.99M	14.55M	13.62M	12.86M	14.39M	11.35M	10.59M	10.36M	5.18M	1.40M	787.00K
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	16.99M	14.55M	13.62M	12.86M	14.39M	11.35M	10.59M	10.36M	5.18M	1.40M	787.00K
Other Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	66.50M	58.95M	49.40M	46.04M	46.57M	37.57M	49.45M	26.89M	13.69M	4.54M	3.14M
Cost & Expenses	66.50M	58.95M	49.40M	46.04M	46.57M	37.57M	49.45M	26.89M	13.69M	4.54M	3.14M
Interest Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	42.00K	0.00	0.00
Interest Expense	2.67M	1.51M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	191.00K	69.00K
Depreciation & Amortization	1.51M	1.46M	1.34M	1.27M	1.18M	912.00K	567.00K	376.00K	334.00K	285.00K	262.00K
EBITDA	-64.76M	-56.97M	-46.94M	-4.35M	-20.05M	3.72M	-814.00K	-24.53M	-12.56M	-4.51M	-1.59M
EBITDA Ratio	-19,925.23%	-11,394.20%	-1,813.05%	-1.58%	-82.91%	9.42%	-1.72%	-1,017.08%	-1,379.45%	-479.19%	-147.23%
Operating Income	-66.27M	-58.45M	-46.94M	-4.35M	-22.38M	1.90M	-2.09M	-24.53M	-12.56M	-3.59M	-2.06M
Operating Income Ratio	-20,390.46%	-11,690.20%	-1,913.66%	-10.43%	-92.55%	4.82%	-4.41%	-1,042.14%	-1,112.13%	-381.53%	-190.30%
Total Other Income/Expenses	-2.58M	-1.39M	1.18M	2.46M	1.18M	905.00K	708.00K	214.00K	-3.35M	-1.40M	135.00K
Income Before Tax	-68.75M	-59.84M	-45.76M	-1.90M	-21.21M	2.81M	-1.38M	-24.32M	-15.91M	-4.99M	-1.92M
Income Before Tax Ratio	-21,153.85%	-11,968.20%	-1,865.55%	-4.55%	-87.69%	7.11%	-2.92%	-1,033.05%	-1,409.03%	-529.72%	-177.82%
Income Tax Expense	2.67M	-2.11M	83.00K	76.00K	72.00K	2.40M	708.00K	214.00K	-3.35M	-1.21M	204.00K
Net Income	-71.42M	-57.83M	-45.89M	-2.01M	-21.30M	407.00K	-1.38M	-24.32M	-15.91M	-4.99M	-1.92M
Net Income Ratio	-21,976.62%	-11,565.80%	-1,870.85%	-4.81%	-88.07%	1.03%	-2.92%	-1,033.05%	-1,409.03%	-529.72%	-177.82%
EPS	-1.59	-1.77	-2.17	-0.11	-1.18	0.02	-0.08	-1.50	-4.46	-1.20	-0.28
EPS Diluted	-1.59	-1.77	-2.17	-0.11	-1.18	0.02	-0.08	-1.50	-4.46	-1.20	-0.28
Weighted Avg Shares Out	45.03M	32.76M	21.10M	18.16M	18.11M	18.07M	17.81M	16.25M	3.57M	4.15M	6.89M
Weighted Avg Shares Out (Dil)	45.03M	32.76M	21.10M	18.16M	18.11M	18.39M	17.81M	16.25M	3.57M	4.15M	6.89M

Analyzing Avrobio (NASDAQ:AVRO) & Editas Medicine (NASDAQ:EDIT)

June 30, 2020thelincolnianonline.com

Avrobio (NASDAQ:AVRO) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk and profitability. Volatility...

Applied Genetic Technologies (NASDAQ:AGTC) Coverage Initiated at Cantor Fitzgerald

June 24, 2020thelincolnianonline.com

Stock analysts at Cantor Fitzgerald assumed coverage on shares of Applied Genetic Technologies (NASDAQ:AGTC) in a report issued on Monday, Marketbeat reports. The brokerage set an “overweight” rating and a $14.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s...

Financial Analysis: INmune Bio (NASDAQ:INMB) and Applied Genetic Technologies (NASDAQ:AGTC)

June 19, 2020thelincolnianonline.com

INmune Bio (NASDAQ:INMB) and Applied Genetic Technologies (NASDAQ:AGTC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, valuation, risk, analyst recommendations and...

US Patent Office Grants Key Risk Test Patent | MarketScreener

June 18, 2020marketscreener.com

Dow Jones Today Rising After the Latest Statement from Federal Reserve Chair

June 17, 2020moneymorning.com

The Dow Jones today is climbing on continued optimism that the Federal Reserve's latest policy can protect the economy from a crash. How certain are they?

Genetic Technologies Announces Pricing of $8.0 Million Public Offering

May 26, 2020marketwatch.com

MELBOURNE, Australia, May 26, 2020 (GLOBE NEWSWIRE via COMTEX) -- MELBOURNE, Australia, May 26, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:...

The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter

May 13, 2020benzinga.com

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Acceleron Pharma Inc (NASDAQ...

The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight

May 10, 2020benzinga.com

The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...